Patent ID: 8222215

Claim:
A method for treating an autoimmune disease responsive to the inhibition of antigen binding to a MHC class II molecule comprising administering to a patient having an autoimmune disease responsive to the inhibition of antigen binding to a MHC class II molecule a compound of formula II: or a pharmaceutically acceptable salt thereof, wherein: R 1 is linear or branched alkyl, alkoxyalkyl, aminoalkyl, alkylaminoalkyl, or dialkylaminoalkyl; X 1 is linear or branched alkyl, hydroxyalkyl, or alkoxyalkyl; X 2 is linear or branched alkyl, heteroalkyl, alkoxycarbonyl, or aminoalkyl; R 2 and R 3 are independently hydrogen, linear or branched alkyl; or R 2 and R 3 taken together form a substituted or unsubstituted 5-7 membered carbocyclic ring; or R 2 and R 3 taken together form a substituted or unsubstituted bicyclic ring; Het is heteroalkyl, aminoalkyl, alkylamido, or a substituted or unsubstituted heterocyclic ring; R 5 and R 6 are independently hydrogen, linear or branched alkyl, or R 5 and R 6 taken together form a substituted or unsubstituted 5-7 membered heterocyclic ring; Z is linear or branched alkyl; or Z taken together with W can form a substituted or unsubstituted 6-7 membered heterocyclic ring; W is linear or branched alkyl when Z is linear or branched alkyl, substituted or unsubstituted aryl or substituted or unsubstituted arylalkyl; A is a substituted or unsubstituted 5-7 membered heteroaryl ring, a substituted or unsubstituted aryl ring, a substituted or unsubstituted 9-14 membered bicyclic ring; or a substituted or unsubstituted 13-17 membered tricyclic ring; m is an integer selected from 0 and 1; n is an integer selected from 0 and 1; t is an integer selected from 0, 1 and 2; p is an integer selected from 0 and 1; and wherein the compounds of formula II contain 0, 1, 2 or 3 residues in the D configuration and the remaining residues are in the L configuration.